Inactive Instrument

Ritter Pharmaceuticals Inc Nasdaq

Equities

US7678361095

Ritter Pharmaceuticals : to Present at the 2015 Aegis Growth Conference

October 06, 2015 at 12:24 pm EDT

LOS ANGELES (October 1, 2015) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (Ritter Pharmaceuticals or the Company), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Michael Step, Chief Executive Officer, will present a corporate overview at the 2015 Aegis Growth Conference on Thursday, October 8, 2015.

Event: 2015 Aegis Growth Conference
Date: Thursday, October 8, 2015
Time: 9:00 a.m. PT

About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Ritter Pharmaceuticals is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. The Company's lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.

Contacts
Investor Contact:
David Burke
dburke@theruthgroup.com
(646) 536-7009

Media Contact:
Eric Kim
ekim@theruthgroup.com
(646) 536-7023

distributed by

Latest news about Ritter Pharmaceuticals Inc

Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	Apr. 16	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
Qualigen Therapeutics, Inc. Enters into A Termination Agreement with Pan-RAS Holdings, Inc	Mar. 28	CI
Qualigen Therapeutics, Inc. announced that it has received $0.55 million in funding from Alpha Capital Anstalt	Feb. 26	CI
Qualigen Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Alpha Capital Anstalt	Feb. 25	CI
Qualigen Therapeutics, Inc. Enters into A License and Sublicense Agreement with Pan-RAS Holdings, Inc	Feb. 22	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	Nov. 07	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M	23-08-15	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors	23-08-01	CI
Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. for $5.8 million.	23-07-23	CI
Qualigen Therapeutics, Inc. Announces Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and Director	23-06-26	CI
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology 2023 Annual Meeting	23-06-05	CI
Qualigen Therapeutics, Inc. Announces the Resignation of Amy Broidrick as President, Chief Strategy and Operating Officer and A Director, Effective June 16, 2023	23-05-19	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q1 Revenue $1.6M	23-05-16	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Posts Q4 Revenue $5M	23-05-02	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Qualigen Therapeutics Receives Nasdaq's Non-Compliance Notice	23-04-24	MT
Qualigen Therapeutics Says QN-302 US Patent Granted; Shares Rise	23-03-21	MT
Qualigen Therapeutics, Inc. to Present Five Posters At the American Association for Cancer Research Annual Meeting 2023	23-03-15	CI
Qualigen Therapeutics, Inc. Announces Publication of Key Data in the Peer-Reviewed Journal Molecules	23-03-08	CI
Qualigen Therapeutics, Inc. Initiates Good Laboratory Practice Toxicology Studies on QN-302	23-01-24	CI
Qualigen Therapeutics, Inc. Announces Executive Changes	23-01-20	CI

Chart Ritter Pharmaceuticals Inc

Duration

Period

More charts

Company Profile

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have an impact on a patient's health. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. RP-G28 selectively increases colonization of lactose-metabolizing bacteria in the colon, such as bifidobacteria and lactobacilli, without increasing the growth of harmful bacteria, such as Escherichia coli (E. coli). The Company has not generated any revenues.

Sector

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company